Overall verdict
Buy
7.1/10
1-year performance
+16.89%
Score breakdown
Up 16.9% over 1 year, 77% of the 52-week range.
Strongest: Profitability 8.8/10. Weakest: Valuation 4.2/10.
5 analysts, target +0.1% vs the price.
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, doctors, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates through two segments: VITAS and Roto-Rooter segments. The company offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
The company also provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Chemed Corporation was incorporated in 1970 and is headquartered in Cincinnati, Ohio.
Sector
Health Care
Industry
Health Care Providers and Services
Primary listing
Nyse
United States
CEO
Kevin McNamara
Founded
1970
Employees
15 811
Revenue / employee
160 014 USD
Next earnings
October 27, 2026
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
557.00 USD
52-week low
365.20 USD
1-year performance
16.89%
Rising
Year-to-date performance
19.95%
Rising
Drawdown
-7.90%
Mild pullback
Position in the 52-week range
77% of range
Against the world ETF
Over 26 years, from December 2000 to September 2026, the share did better than the world ETF once risk is accounted for.
$10,000 placed at the end of December 2000 are worth today
| Chemed | $300,413 |
| World ETF | $66,618 |
| S&P 500 | $92,038 |
| Risk-free placement | $15,841 |
The risk
- Shaking:the share moves 1.9 times as much as the world ETF.
- Worst fall:-49 % between May 2007 and April 2008. $10,000 placed at the top fell to $5,090. The world ETF, at worst: -53 %. Back to its high in 36 months.
Chemed earned 5 times as much as the world ETF since 2000
Value of $10,000 placed at the end of December 2000, dividends reinvested, in dollars
- Chemed: $300,413
- World ETF: $66,618
- S&P 500: $92,038
- Risk-free placement: $15,841
Share price without dividends; the world ETF and the index reinvest theirs. A dividend payer is therefore understated here.
Based on past performance. This is not a recommendation.
Range: 462.72 USD - 479.44 USD (comparables only)
The price implies growth of 5.46% per year; the company grows at -1.20%.
Gross margin 30.4%, net margin 10.6%, ROIC 23.1%, ROE 27.1%.
Net margin
10.60%
Exceptional
Sector 3.86%|S&P 13.15%
Gross margin
30.44%
Fair
Return on equity (ROE)
27.11%
Exceptional
Sector 7.28%|S&P 16.60%
Return on invested capital (ROIC)
23.07%
Exceptional
Free cash flow margin (FCF)
12.47%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.18x
Fair
Margin stability
2.6 pts
Steady
Revenue to net income
Growth
6.0/10Revenue up 8.8% over 1 year, 4.0% a year over 5, EPS -1.2% a year over 5.
Revenue (trailing 12 months)
2.6Md USD
Revenue growth (1y)
8.80%
Solid
Revenue growth (3y)
18.50%
Solid
EPS growth (1y)
43.67%
Hyper-growth
EPS CAGR (5y)
-1.20%
Declining
EPS revisions (3 months)
4.73%
Revised up
Valuation
4.2/10P/E 25.8x, forward P/E 22.0x, EV/EBITDA 16.1x, PEG 11.09. The multiple sits in the 36th percentile of its own 5-year history.
P/E (TTM)
25.8x
Fair
Sector 27.7x|S&P 24.1x
Forward P/E
22.0x
Fair
EV / EBITDA
16.1x
Fair
Sector 13.5x|S&P 15.1x
PEG
11.09
Very expensive
Sector 1.23|S&P 0.92
Fair value (reverse DCF)
471.08 USD
Fairly priced
P/E vs its own 5-year history
among the 36% lowest valuations
Cheaper than usual
Market cap
6.7Md USD
Financial strength
8.5/10Cash covers 12.2% of the debt, net debt/EBITDA 0.2x.
Net debt / EBITDA
0.2x
Very solid
Gearing (net debt / equity)
34.78%
Solid
Cash
40.2M USD
Cash / market cap
0.60%
Stretched
Cash / total debt
12.22%
Stretched
Interest coverage
106.5x
Very solid
Net debt
289M USD
Equity
831M USD
Closed daily candles, 2 years
Last close on October 23, 2026: 512.98 USD
- MM20508.69
- MM50515.25
- MM200460.80
- RSI 1451.9
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+1.81%
200-day average slope, 3 months
+6.19%
50-day average slope, 1 month
-1.48%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.06 % per day
Volatility change
-29.31%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 23.28 (3) | 25.49 (5) | 2 721 (5) | 517 (5) | 309 (4) |
| 2027 | 25.73 (3) | 27.52 (5) | 2 886 (5) | 548 (5) | 336 (4) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 25, 2026.
Same sub-industry: 75 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CHE | 7.1 | 6.7 | 6.7Md USD | 25.8x | 10.6 % | 8.8 % | 23.1 % | 0.2x | 4.8 % | 16.9 % | ||
| 2 | DVA | 7.0 | 6.9 | 11.7Md USD | 15.5x | 5.9 % | 5.2 % | 6.9 % | 4.5x | 13.7 % | 43.2 % | ||
| 3 | CI | 6.8 | 7.2 | 81.1Md USD | 12.7x | 2.3 % | 6.5 % | 9.3 % | 1.8x | 11.2 % | 0.3 % | ||
| 4 | DGX | 6.6 | 6.2 | 26.7Md USD | 24.1x | 9.5 % | 10.0 % | 8.4 % | 2.8x | 5.2 % | 32.9 % | ||
| 5 | LH | 6.4 | 6.0 | 26.7Md USD | 27.2x | 7.0 % | 5.8 % | 6.8 % | 2.4x | 4.3 % | 15.7 % | ||
| 6 | BTSG | 6.3 | 5.0 | 11.9Md USD | 44.9x | 1.7 % | 23.0 % | 5.7 % | 4.6x | 3.4 % | 82.2 % | ||
| 7 | FME | 5.9 | 6.3 | 12.1Md USD | 12.2x | 4.8 % | 1.4 % | 4.3 % | 2.7x | 16.9 % | -14.0 % | ||
| 8 | CVS | 5.6 | 4.8 | 120Md USD | 24.7x | 1.2 % | 7.2 % | 3.2 % | 4.1x | 9.8 % | 15.1 % | ||
| 9 | GH | 5.1 | 3.4 | 22.7Md USD | Not meaningful (loss) | -38.3 % | 44.3 % | -37.0 % | -1.5x | -1.0 % | 149.3 % |
